$50.2 Million is the total value of Healthcare Value Capital, LLC's 23 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 22.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | GILEAD SCIENCES INC | $5,165,000 | +6.6% | 75,000 | 0.0% | 10.29% | -4.7% | |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $3,982,000 | +11.6% | 100,000 | 0.0% | 7.93% | -0.2% | |
| PFE | PFIZER INC | $3,916,000 | +8.1% | 100,000 | 0.0% | 7.80% | -3.3% | |
| ALKS | Buy | ALKERMES PLC | $3,678,000 | +96.9% | 150,000 | +50.0% | 7.33% | +76.2% |
| BMY | Buy | BRISTOL-MYERS SQUIBB CO | $3,341,000 | +111.7% | 50,000 | +100.0% | 6.66% | +89.4% |
| MRK | Buy | MERCK & CO INC | $3,111,000 | +101.8% | 40,000 | +100.0% | 6.20% | +80.5% |
| AZN | Buy | ASTRAZENECA PLCsponsored adr | $2,995,000 | +140.9% | 50,000 | +100.0% | 5.97% | +115.6% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $2,900,000 | -8.2% | 500,000 | +11.1% | 5.78% | -17.9% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $2,574,000 | +15.1% | 200,000 | 0.0% | 5.13% | +3.0% | |
| AMYT | Buy | AMRYT PHARMA PLCsponsored ads | $2,426,000 | +12.0% | 200,000 | +28.6% | 4.83% | +0.2% |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $2,364,000 | -0.3% | 100,000 | 0.0% | 4.71% | -10.8% | |
| ATRS | ANTARES PHARMA INC | $2,180,000 | +6.1% | 500,000 | 0.0% | 4.34% | -5.1% | |
| TYME | TYME TECHNOLOGIES INC | $1,890,000 | -29.2% | 1,500,000 | 0.0% | 3.77% | -36.7% | |
| VYNE | Buy | VYNE THERAPEUTICS INC | $1,580,000 | -42.3% | 450,000 | +12.5% | 3.15% | -48.4% |
| GNLN | Buy | GREENLANE HLDGS INCcl a | $1,565,000 | +18.0% | 350,000 | +40.0% | 3.12% | +5.6% |
| MDXG | New | MIMEDX GROUP INC | $1,564,000 | – | 125,000 | +100.0% | 3.12% | – |
| SQQQ | New | PROSHARES TRcall | $914,000 | – | 100,000 | +100.0% | 1.82% | – |
| SPXU | Sell | PROSHARES TRcall | $911,000 | -61.5% | 50,000 | -50.0% | 1.82% | -65.6% |
| AMRN | Sell | AMARIN CORP PLCcall | $876,000 | -53.0% | 200,000 | -33.3% | 1.74% | -57.9% |
| IRWD | IRONWOOD PHARMACEUTICALS INCcall | $644,000 | +15.2% | 50,000 | 0.0% | 1.28% | +3.1% | |
| VIXY | New | PROSHARES TR IIcall | $602,000 | – | 25,000 | +100.0% | 1.20% | – |
| ADMS | ADAMAS PHARMACEUTICALS INC | $528,000 | +10.0% | 100,000 | 0.0% | 1.05% | -1.6% | |
| GMDA | Buy | GAMIDA CELL LTD | $481,000 | +18.8% | 75,000 | +50.0% | 0.96% | +6.2% |
| VIXY | Exit | PROSHARES TR IIcall | $0 | – | -100,000 | -100.0% | -2.08% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -2.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC | 20 | Q3 2021 | 31.3% |
| GLAXOSMITHKLINE PLC | 20 | Q3 2021 | 16.1% |
| PFIZER INC | 19 | Q3 2021 | 17.9% |
| TYME TECHNOLOGIES INC | 17 | Q3 2021 | 40.3% |
| ASTRAZENECA PLC | 14 | Q3 2021 | 12.9% |
| QUEST DIAGNOSTICS INC | 14 | Q3 2016 | 9.5% |
| CRYOLIFE INC | 13 | Q1 2017 | 6.6% |
| ANTARES PHARMA INC | 13 | Q3 2021 | 6.7% |
| AMARIN CORP PLC | 13 | Q3 2021 | 4.9% |
| CYTOKINETICS INC | 13 | Q3 2016 | 1.7% |
View Healthcare Value Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| NOVELION THERAPEUTICS INC. | September 20, 2019 | 1,400,000 | 7.4% |
View Healthcare Value Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-15 |
| 13F-HR | 2020-02-14 |
| 13F-HR | 2019-11-14 |
| SC 13D/A | 2019-09-20 |
View Healthcare Value Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.